Randall M. Stevens - Concepedia

Author

Randall M. Stevens

Friedrich-Alexander-Universität Erlangen-Nürnberg ORCID

Also Known As

G Summers, J Isaacs, R M Stevens, R Stevens, R. M. STEVENS, R. M. Stevens, R. Stevens, R.-M. Stevens, R.M. Stevens, RANDALL STEVENS

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

Friedrich-Alexander-Universität Erlangen-Nürnberg Stanford University Bristol-Myers Squibb (Switzerland)Schön Klinik Hamburg Eilbek NIHR Leeds Musculoskeletal Biomedical Research Unit

About

Randall M. Stevens is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in medicine, autoimmune disease, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Health Sciences	4	4	331
3	Engineering	2	2	47
4	Natural Sciences	1	1	16
5	Public Health	1	1	110

Randall M. Stevens

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis Jonathan Edwards, L Szczepański, Jacek Szechiński, New England Journal of Medicine	2004	2.6K
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Papp, Kristian Reich, Craig L. Leonardi, Journal of the American Academy of Dermatology Autoimmune DiseaseMedicinePhase IiiClinical TrialsPlaque Psoriasis	2015	649
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, Annals of the Rheumatic Diseases	2014	435
Treatment of arthritis with topical capsaicin: a double-blind trial. Chad Deal, Thomas J. Schnitzer, Ellen A. Lipstein, PubMed	1991	297
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, Annals of the Rheumatic Diseases	2016	275
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study Gülen Hatemi, Melike Melikoğlu, Recep Tunç, New England Journal of Medicine	2015	229
Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis Manish Kothari, Ali Guermazi, G.v. Ingersleben, European Radiology Musculoskeletal ImagingFixed-flexion RadiographyBiomechanicsOsteoarthritisJoint Replacement	2004	220
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann, The Journal of Rheumatology	2016	206
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study Georg Schett, J. Wollenhaupt, Kim Papp, Arthritis & Rheumatism	2012	202
Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop Jason W. Busse, Susan J. Bartlett, Maxime Dougados, The Journal of Rheumatology	2015	170

Page 1